Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: The impact of varying the discount rate for health

Vaccine

Volumn 27, Issue 6, 2009, Pages 846-852

  de Vries, Robin ^a   Klok, Rogier M ^a   Brouwers, Jacobus R B J ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cost effectiveness; Discount rate; Helicobacter pylori

Indexed keywords

HELICOBACTER PYLORI VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH PROGRAM; HEALTH STATUS; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PEPTIC ULCER; POPULATION; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; STOMACH CANCER; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFANT; INFANT, NEWBORN; MALE; MARKOV CHAINS; MIDDLE AGED; NETHERLANDS; PREVALENCE; YOUNG ADULT;

EID: 58249109701     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.081     Document Type: Article

References (45)

1. Roosendaal R., Kuipers E.J., Buitenwerf J., van Uffelen C., Meuwissen S.G., van Kamp G.J., et al. Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 92 9 (1997) 1480-1482
2. De Vries A.C., van Driel H.F., Richardus J.H., Ouwendijk M., Van Vuuren A.J., De Man R.A., et al. Migrant communities constitute a possible target population for primary prevention of Helicobacter pylori-related complications in low incidence countries. Scand J Gastroenterol 43 (2008) 403-409
3. Mourad-Baars P.E.C., Verspaget H.W., Mertens B.J.A., and Luisa Mearin M. Low prevalence of Helicobacter pylori infection in young children in the Netherlands. Euro J Gastroenterol Hepatol 19 (2007) 213-216
4. Frenk Jr. R.W., and Clemens J. Helicobacter in the developing world. Microb Infect 5 (2003) 705-713
5. Ford A., Delaney B., Forman D., and Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev October (4) (2004) CD003840
6. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Therap 13 (1999) 851-856
7. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Infections with Helicobacter pylori. In: Schistosomes, liver flukes and Helicobacter pylori. Lyon: IARC; 1994. p. 177-240.
8. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345 11 (2001) 784-889
9. Fukase K., Kato M., Kikuchi S., Inoue K., Uemura N., Okamoto S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. Lancet 372 (2008) 392-397
10. Statistics Netherlands. http://statline.cbs.nl [accessed May 2008].
11. Polder JJ, Takken J, Meerding WJ, Kommer GJ, Stokx LJ. Cost of illness in the Netherlands. RIVM rapport nr. 270751005. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu, Erasmus MC, Instituut Maatschappelijke Gezondheidszorg, Bohn Stafleu Van Loghum; 2002.
12. Malaty H.M., and Nyren O. Epidemiology of Helicobacter pylori infection. Helicobacter 8 Suppl. 1 (2003) 8-12
13. In: Stratton K.R., Durch J.S., and Lawrence R.S. (Eds). Vaccines for the 21st century: a tool for decisionmaking (2000), Committee to Study Priorities for Vaccine Development/Division of Health Promotion and Disease Prevention Institute of Medicine/National Academy Press, Washington (DC)
14. Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12 (2007) 89-102
15. Malfertheiner P., Schultze V., Rosenkranz B., Kaufmann S.H.E., Ulrichs T., Novicki D., et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 135 (2008) 787-795
16. Welte R., van den Dobbelsteen G., Bos J.M., de Melker H., van Alphen L., Spanjaard L., et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine 23 4 (2004) 470-479
17. Riteco J.A., De Heij L.J.M., van Luijn J.C.F., and Wolff I. Guidelines for pharmacoeconomic research (1999), Amstelveen College voor Zorgverzekeringen
18. Keeler E.B., and Cretin S. Discounting of life-saving and other non-monetary effects. Manage Sci 29 3 (1983) 300-306
19. Weinstein M.C., and Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296 13 (1977) 716-721
20. Dutch Guidelines for Pharmacoeconomic Research. Health Care Insurance Board; 2006. http://www.ispor.org/PEguidelines/source/PE_guidelines_english.pdf.
21. Klok R.M., Brouwer W.B.F., Annemans L.A., Bos J.M., and Postma M.J. Towards a healthier discount procedure. Exp Rev Pharmacoecon Outcome Res 5 1 (2005) 59-63
22. Gravelle H., and Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 10 7 (2001) 587-599
23. Briggs A., and Sculpher M. An introduction to Markov models for economic evaluation. Pharmacoeconomics 13 4 (1998) 397-409
24. Miller D.K., and Homan S.M. Determining transition probabilities: confusion and suggestions. Med Decis Making 14 (1994) 52-58
25. Rümke HC, Visser HKA. Childhood vaccinations anno 2004. I. Effectiveness and acceptance of the Dutch National Vaccination Programme [In Dutch: Vaccinaties op de kinderleeftijd anno 2004. I. Effectiviteit en acceptatie van het Rijksvaccinatieprogramma]. Nederlands Tijdschrift voor Geneeskunde 2004;148(8):356-63.
26. Rupnow M.F.T., Owens D.K., Shachter R., and Parsonett J. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine methodology. Helicobacter 4 4 (1999) 272-280
27. Slobbe LCJ, Kommer GJ, Smit JM, Groen J, Meerding WJ, Polder JJ. Kosten van Ziekten in Nederland 2003. RIVM report 270751010, Bilthoven; 2006.
28. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17 5 (2000) 479-500
29. Vandenbroucke JP, Hofman A. Basics of epidemiology [In Dutch: Grondslagen der epidemiologie]. 6 ed. Maarssen: Elsevier/Bunge; 1999.
30. Rothman K.J. Modern epidemiology (1986), Little, Brown and Company, Boston/Toronto
31. van Hout B.A., Al M.J., Gordon G.S., and Rutten F.F. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 3 5 (1994) 309-319
32. Fenwick E., O'Brien B.J., and Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 13 5 (2004) 405-415
33. Bos J.M., and Postma M.J. Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?. Exp Rev Pharmacoecon Outcome Res 4 3 (2004) 247-250
34. Loffeld R.J. Helicobacter pylori and reflux esophagitis in Turkish patients living in the Zaanstreek region in the Netherlands. Digest Dis Sci 48 9 (2003) 1846-1849
35. Dutch national immunization program (RVP). http://www.nvi-vaccin.nl/?id=564 [accessed May 2008].
36. Gravelle H., and Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 10 (2001) 587-599
37. Brouwer W.B., Niessen L.W., Postma M.J., and Rutten F.F. Need for differential discounting of costs and health effects in cost effectiveness analyses. Brit Med J 331 7514 (2005) 446-448
38. Bos J.M., Postma M.J., and Annemans L.A. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 23 7 (2005) 639-649
39. Bos J.M., Beutels P., Annemans L.A., and Postma M.J. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics 22 18 (2004) 1171-1179
40. Van der Pol M., and Cairns J.A. Negative and zero time preference for health. Health Econ 9 (2000) 171-175
41. MacKeigan L.D., Gafni A., and O'Brien B.J. Double discounting of QALYs. Health Econ 12 (2003) 165-169
42. Loewenstein G., and Prelec D. Negative time preference. Am Econ Assoc Paper Proc 81 2 (1991) 347-352
43. Klok R.M., Arents N.L.A., de Vries R., Thijs J.C., Brouwers J.R., Kleibeuker J.H., et al. Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat with prompt endoscopy in primary care. Clin Therap 27 (2005) 1647-1657
44. Kurata J.H., and Nogawa A.N. Meta-analysis of risk factors for peptic ulcer: nonsteroidal antiinflammatory drugs, Helicobacter pylori and smoking. J Clin Gastroenterol 24 1 (1997) 2-17
45. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Therap 13 7 (1999) 851-856